French specialty vaccine company Valneva and U.S. drugmaker Pfizer reported positive results from the companies’ Phase II study on a vaccine candidate for Lyme disease.

Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.

French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.

German biotech firm CureVac enrolled the first participant for a Phase 2b/3 clinical trial of the company’s Covid-19 vaccine candidate.